Whats new
Whats new.
Maxim Group - New P2/3 AIPAC-003 Study Initiated with More Aggressive Dosing and OS Primary in Breast Cancer; Rating Buy, $8 tgt (Analyst: Jason McCarthy, PhD)
March 14th 2023
For a copy of this analyst report please contact your Maxim analyst Jason McCarthy - jmccarthy@maximgrp.com